Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > Probability of Positive ROI with ATE - Jan 22. Market Close
View:
Post by mstrmnd on Jan 22, 2021 4:44pm

Probability of Positive ROI with ATE - Jan 22. Market Close

Hi longs, 

Curious as to what the almost insiders that know this company inside out think of the following from the current entry point today (say $4.00 to keep round numbers): 

Projected 1-year ROI  =  
Projected 3-year ROI  = 
Projected 5-year ROI  = 

Based on your calculated risk, kindly state probability of achieving projected ROIs (low, average, or high probability).

From a tax efficiency prespective, is it fair to say, ATE.TO via TFSA, RRSP, or other tax efficient vehicle could be one of the best Canadian companies to invest in right now for investors looking long-term?  Where if you can afford to hold for 3-5 years, it is a very low risk investment with a tremendous short-term and long-term upside?

On my assessment it looks like the long-term ROI is in the range of 10x to 300x+ from market close January 22, 2021, where after the COVID storm, there will be a natural lift on NASDAQ timed to capital markets where Antibe Holdings will be pursuing multiple lines of therapeutics in their pipeline in the following markets:
1. Chronic Pain (Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis)
2. Inflammatory Bowel Disease (Ulcerative Colitis and Crohn's Disease)

Will we see a jump in the SP once amalgamated with Antibe Holdings, because now the key has opened the lock where the combined entity value jumps (amalgamation, market marker opens at new SP)? 

Have a great weekend everyone!  GLTA
Comment by Layth1990 on Jan 22, 2021 5:04pm
many factors are keeping stock price down. covid is one of them as it might affect phase 3 and cause delay. 2nd, we don't have enough cash and we still don't have any partners.3rd, investors don't like dilution. dilution will happen regardless in my openion. what is the worst thing could happen ?  no partners and phase 3 will be postponed. 2022 we might see phase 3 ? that is okay ...more  
Comment by Blazesb on Jan 22, 2021 6:01pm
Layth1990.  You speak far too much common sense to be treated seriously.  This board is strictly for wishes and dreams untethered to the facts you cite. Well done. 
Comment by 3burtc on Jan 23, 2021 6:21am
Such a refreshing opinion, thank you! Of course i do have all the aliases on ignore lol.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities